| Hypercholesterolemia
Leqvio vs Praluent
Side-by-side clinical, coverage, and cost comparison for hypercholesterolemia.Deep comparison between: Leqvio vs Praluent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPraluent has a higher rate of injection site reactions vs Leqvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Praluent but not Leqvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Leqvio
Praluent
At A Glance
SC injection
Every 6 months (after initial doses)
PCSK9 siRNA
SC injection
Every 2-4 weeks
PCSK9 inhibitor
Indications
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Myocardial Infarction
- Coronary heart disease
- Cerebrovascular accident
- Angina, Unstable
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
Dosing
Hypercholesterolemia, Familial hypercholesterolemia - heterozygous, Homozygous Familial Hypercholesterolemia 284 mg SC injection initially, again at 3 months, then every 6 months; administered by a healthcare professional into abdomen, upper arm, or thigh.
Hypercholesterolemia, Myocardial Infarction, Coronary heart disease, Cerebrovascular accident, Angina, Unstable 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks; may adjust to 150 mg SC every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (adults on LDL apheresis), Homozygous Familial Hypercholesterolemia 150 mg SC once every 2 weeks; may be administered without regard to timing of LDL apheresis.
Familial hypercholesterolemia - heterozygous (pediatric, <50 kg) 150 mg SC once every 4 weeks; may adjust to 75 mg SC once every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (pediatric, >=50 kg) 300 mg SC once every 4 weeks; may adjust to 150 mg SC once every 2 weeks if LDL-C response is inadequate.
Contraindications
- Prior serious hypersensitivity reaction to inclisiran or any excipient in LEQVIO (including anaphylaxis and angioedema)
- Previous serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT
Adverse Reactions
Most common (>=3%) Injection site reaction, arthralgia, bronchitis
Postmarketing Anaphylaxis, angioedema, rash, pruritus, urticaria
Most common (>=2%) Injection site reactions, influenza, diarrhea, myalgia, muscle spasms, contusion
Serious Hypersensitivity vasculitis, nummular eczema, angioedema
Postmarketing Angioedema, influenza-like illness
Pharmacology
PCSK9 siRNA; inclisiran is a double-stranded siRNA conjugated with GalNAc that directs catalytic breakdown of PCSK9 mRNA in hepatocytes, increasing LDL-C receptor recycling and expression on the hepatocyte cell surface to reduce circulating LDL-C.
Alirocumab is a human monoclonal antibody that inhibits PCSK9, a protein that promotes LDL receptor degradation on hepatocytes, thereby increasing LDL receptor availability and lowering circulating LDL-C levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Leqvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Praluent
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Leqvio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Praluent
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Leqvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Praluent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Hypercholesterolemia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$50/momo
MyPraluent Copay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LeqvioView full Leqvio profile
PraluentView full Praluent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.